Core Insights - Cardinal Health's accelerating specialty strategy is central to its earnings expansion, with adjusted EPS guidance for fiscal 2026 raised to $10.15-$10.35, indicating a 23-26% year-over-year growth [1][10] Financial Performance - The Pharmaceutical and Specialty Solutions segment is driving momentum, benefiting from strong demand for brand and specialty drugs, leading to significant profit growth supported by a favorable product mix and cost management [2] - Cardinal Health expects specialty revenues to exceed $50 billion in fiscal 2026, indicating substantial growth in this higher-margin segment [3][10] - The company has raised its fiscal 2026 adjusted EPS guidance, reflecting strong operational execution and continued demand across its pharmaceutical platform [1][10] Strategic Initiatives - A key component of the growth strategy is the rapid expansion of Cardinal Health's specialty ecosystem, including partnerships with physician practices through MSO platforms [4][6] - The acquisition of Solaris Health enhances Cardinal Health's capabilities in the urology specialty, further expanding its footprint [4] - The biopharma services business, including the Sonexus patient-support platform, is gaining traction, reinforcing Cardinal Health's role in the specialty value chain [5][6] Industry Context - Competitors McKesson and Cencora are also expanding into specialty pharmaceuticals, with McKesson reporting double-digit revenue and EPS growth driven by oncology services [7][8] - Cencora reported 12% operating income growth and 9% EPS growth, largely due to its U.S. Healthcare Solutions segment and specialty drug demand [9] Valuation and Estimates - Cardinal Health's shares have gained 5.2% over the past six months, outperforming the industry average of 1.4% [12] - The company trades at a forward price-to-earnings ratio of 19.45, above the industry average and its five-year median of 13.46 [13] - The Zacks Consensus Estimate for fiscal 2026 earnings implies a 25.1% rise from the previous year [14]

Core Insights - AMN Healthcare Services, Inc. reported adjusted earnings per share (EPS) of 22 cents for Q4 2025, a decline of 70.7% year over year, aligning with Zacks Consensus Estimate [1] - The company’s revenues for Q4 2025 were $748.2 million, reflecting a year-over-year increase of 1.8% and surpassing the Zacks Consensus Estimate by 3.3% [2] Financial Performance - Full-year 2025 revenues totaled $2.73 billion, an 8.5% decrease from 2024, but still beating the Zacks Consensus Estimate by 0.7% [2] - The GAAP loss per share for Q4 was 20 cents, compared to a loss of $4.90 in the same quarter last year [1] - Adjusted EPS for the full year 2025 was $1.36, down 58.9% from 2024, also in line with the Zacks Consensus Estimate [1] Segment Performance - The Nurse and Allied Solutions segment generated revenues of $491 million in Q4, an 8% increase year over year, with $124 million attributed to labor disruption events [4] - The Physician and Leadership Solutions segment reported revenues of $170 million, down 2% year over year, with locum tenens revenues flat at $136 million [5] - The Technology and Workforce Solutions segment saw revenues decline by 18% year over year to $88 million, with language interpretation services down 9% [6] Margin and Expenses - Gross profit for Q4 fell 11% year over year to $195.1 million, with gross margin contracting by 370 basis points to 26.1% [7] - Selling, general, and administrative expenses decreased by 4.3% year over year to $152.1 million [7] - Operating profit was $8.1 million, a significant improvement from an operating loss of $202.6 million in the previous year, resulting in an operating margin of 1.1% [7] Future Guidance - For Q1 2026, AMN expects revenues between $1.225 billion and $1.240 billion, indicating a growth of 78-80% compared to the previous year [11] - The company anticipates a 137-139% revenue increase in the Nurse and Allied Solutions segment for Q1, while expecting declines of 5-8% in the Physician and Leadership Solutions segment and 16-18% in the Technology and Workforce Solutions segment [12] Strategic Outlook - Management noted that the company gained market share in nurse and allied staffing, which is expected to continue into 2026 [14] - The rollout of enhanced capabilities within the ShiftWise Flex platform is projected to improve client retention and new business acquisition [16] - AMN sees a path to sustainable organic revenue growth of 4% to 6% annually beyond 2026, with disciplined expense growth [17]

Core Viewpoint - McKesson Corporation's shares have surged approximately 16 percent in morning trading, reaching $956.61, attributed to the positive impact of its recent third-quarter financial results announcement [1][2]. Group 1: Stock Performance - McKesson's shares are currently trading at $956.61, reflecting an increase of 16.27 percent or $133.76 [1]. - The stock opened at $867.97 and has peaked at $964.94 during the trading session [1]. - Over the past year, McKesson's stock has fluctuated between $570.51 and $964.94 [1]. Group 2: Financial Results - The company's third-quarter earnings rose to $1.186 billion, equating to $9.59 per share, compared to $879 million or $6.95 per share in the previous year [2].

Core Insights - Cardinal Health reported a strong second quarter for fiscal year 2026, with revenues of $65.6 billion, a 19% increase from the previous year, and non-GAAP operating earnings rising 38% to $877 million [1][2][10] Financial Performance - Revenue for Q2 FY26 was $65.6 billion, up from $55.3 billion in Q2 FY25, reflecting a 19% year-over-year growth [2] - GAAP operating earnings increased by 29% to $707 million, while GAAP diluted EPS rose 19% to $1.97 [1][2] - Non-GAAP diluted EPS increased 36% to $2.63, driven by higher non-GAAP operating earnings and a lower share count [1][2] Segment Results - **Pharmaceutical and Specialty Solutions Segment**: Revenue increased 19% to $60.7 billion, with segment profit rising 29% to $687 million, attributed to growth in brand and specialty pharmaceutical sales [3][4] - **Global Medical Products and Distribution Segment**: Revenue grew 3% to $3.3 billion, with segment profit surging 106% to $37 million, driven by existing customer volume growth and cost optimization initiatives [5][6] - **Other Segment**: Revenue increased 34% to $1.7 billion, with segment profit up 52% to $179 million, supported by growth in at-Home Solutions and other operating segments [7][8] Fiscal Year 2026 Outlook - Cardinal Health raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, reflecting a growth of 23% to 26% [9][10] - Segment profit growth expectations were adjusted: Pharmaceutical and Specialty Solutions to 20%-22%, Global Medical Products and Distribution to approximately $150 million, and Other segment to 33%-35% [11] Share Repurchase and Acquisitions - The company completed a $375 million accelerated share repurchase program in Q2 FY26, totaling $750 million in share repurchases for the fiscal year [20] - Cardinal Health's Specialty Alliance acquired Solaris Health, enhancing its multi-specialty MSO platform [20]

Core Insights - Investors should conduct a thorough review of a company's financial background rather than relying solely on real-time trading numbers, especially in a volatile market [1] - The interest coverage ratio is a critical indicator of a company's ability to meet its debt obligations, particularly in a tighter financial environment [2][4] Financial Metrics - Companies like Casey's General Stores, Brinker International, Cardinal Health, and Flowserve have strong interest coverage ratios, indicating their capacity to service debt [3] - The interest coverage ratio is calculated as Earnings before Interest & Taxes (EBIT) divided by Interest Expense, providing insight into a company's financial stability [5] - A ratio below 1 indicates potential default risk, while a higher ratio suggests a company can withstand financial challenges [7] Investment Strategy - A favorable investment strategy includes selecting stocks with an interest coverage ratio above the industry average, a Zacks Rank of 1 or 2, and a VGM Score of A or B [8][11] - Stocks meeting these criteria are likely to outperform in various market conditions [11] Company Highlights - Casey's General Stores has a Zacks Rank of 1, with a trailing four-quarter earnings surprise of 24.1% and projected sales and EPS growth of 8.8% and 18.8%, respectively, leading to a 44.6% stock increase over the past year [10][12] - Cardinal Health holds a Zacks Rank of 2, with a trailing earnings surprise of 9.4% and projected sales and EPS growth of 16.4% and 21.5%, respectively, resulting in a 71.5% stock surge [12][13] - Brinker International, also with a Zacks Rank of 2, has a trailing earnings surprise of 8.2% and projected sales and EPS growth of 7.7% and 18.7%, but its stock has declined by 16.6% [13][14] - Flowserve, with a Zacks Rank of 2, shows a trailing earnings surprise of 10.5% and projected sales and EPS growth of 4.6% and 31.9%, leading to a 26.2% stock increase [14][15]

Core Viewpoint - McKesson Corporation (MCK) is perceived to receive insufficient attention from investors, particularly those focused on value investing, despite possessing characteristics of an ideal value investment [1] Company Characteristics - McKesson exhibits all the traits of a strong value investment opportunity, making it attractive for investors seeking undervalued stocks [1] Analyst Background - The analyst has over six years of experience in the investment sector, with a background in equity analysis across various industries, emphasizing the importance of understanding the narratives behind financial statements [1]

Summary of Healthcare Services Conference Call Industry Overview - The conference call focused on the **Healthcare Services** industry, particularly the **Managed Care** sector and its outlook for 2026, highlighting potential margin improvements and policy clarity as positive factors for growth [4][10][11]. Key Points and Arguments Managed Care - **Earnings Recovery**: Most Managed Care Organizations (MCOs) are expected to reach trough earnings in 2026, with potential upward revisions thereafter. Medicare Advantage (MA) is anticipated to drive margin upside, while skepticism remains around Medicaid and ACA Exchanges until MCOs demonstrate margin improvements [5][12]. - **Enrollment Trends**: MCOs are targeting enrollment declines to improve margins, with companies like CVS, ELV, and UNH focusing on this strategy. Conversely, HUM is positioned for membership growth [12][52]. - **Regulatory Environment**: The 2026 midterms are expected to create gridlock, reducing the likelihood of major policy changes outside of CMS rulemaking, which could stabilize the operating environment for MCOs [5][12]. Pharmaceutical Distributors - **Strong Fundamentals**: The current strength in results for pharmaceutical distributors is attributed to stable generic pricing, MSO growth, and a robust specialty pipeline. Companies like McKesson (MCK) and Cencora (COR) are favored due to their strong specialty businesses [9][16]. - **M&A Activity**: Distributors led M&A activity in 2025, with expectations for continued integration and organic investment in MSO capabilities in 2026 [25]. Labs and Healthcare Facilities - **Demand Trends**: Labs are expected to see steady demand trends with a healthy backdrop in diagnostics. Regulatory uncertainties may impact pricing and mix development, but overall operating conditions are stable [9][12]. - **Facility Performance**: Healthcare facilities are positioned to benefit from favorable utilization trends, although policy uncertainty remains a concern for future earnings growth [12][16]. Additional Insights - **Investment Picks**: Top investment picks include UnitedHealth (UNH) and CVS Health (CVS) for their cleaner stories, while Cigna (CI) is seen as attractive but with more complexities [5][14][17]. - **Margin Pressures**: Medicaid remains a challenge, with companies like ELV and UNH guiding for margin pressure in 2026. Investment income is also expected to be a headwind for managed care [5][12]. - **Market Dynamics**: The ACA Exchanges are viewed as a swing factor for MCOs, with a wide range of outcomes expected due to potential shifts in market morbidity [12][43]. Conclusion The healthcare services industry is navigating a complex landscape with potential for margin recovery and growth driven by Medicare Advantage, while facing challenges in Medicaid and ACA Exchanges. The focus on regulatory clarity and strategic M&A activity will be crucial for companies as they prepare for 2026 and beyond.

Group 1 - Cencora (COR) has not received significant coverage since early August, despite its increasing relevance and strong fundamentals [1] - The company is largely overlooked by investors, yet it is viewed as one of the most attractive names in the market [1]

Core Viewpoint - McKesson (MCK) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for McKesson suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10]. Recent Performance of McKesson - McKesson is expected to earn $38.05 per share for the fiscal year ending March 2026, with no year-over-year change, but the Zacks Consensus Estimate has increased by 2.3% over the past three months [8].

Core Viewpoint - Cardinal Health (CAH) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Cardinal suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - Cardinal's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for Cardinal - Cardinal is expected to earn $9.37 per share for the fiscal year ending June 2026, with no year-over-year change, but the Zacks Consensus Estimate has increased by 4.6% over the past three months [8].